AstraZeneca (LSE:AZN) received EU approval for its cancer treatment Imfinzi, marking a significant product-related milestone.

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

The strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca also has a profit-sharing deal with ...

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

Imfinzi is approved in the US and other countries in this setting based on the NIAGARA results. Regulatory applications for this indication are currently under review in Japan and several other ...